{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:34:11Z","timestamp":1788352451228,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","award":["MRACE efficiency grant number 2019-19214"],"award-info":[{"award-number":["MRACE efficiency grant number 2019-19214"]}],"id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliat Med"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Many patients in the last phase of life use anticoagulants. There is little evidence on the benefits and risks of (dis)continuation of anticoagulant therapy in this phase, leaving healthcare professionals with a complex clinical dilemma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To gain an in-depth understanding of the experiences, perspectives, and preferences of healthcare professionals regarding decision-making about anticoagulant therapy in the last phase of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Semi-structured in-depth interviews were conducted and analyzed using a thematic content analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/participants:<\/jats:title>\n                    <jats:p>This study was performed in the Dutch Federation of Anticoagulation Clinics, two hospitals, two hospices, and two palliative home care groups in the Netherlands. Thirty-two healthcare professionals regularly involved in care for patients in the last phase of life were interviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Healthcare professionals experienced decision-making regarding anticoagulant therapy in the last phase of life as difficult and multifactorial, due to a lack of knowledge on the incidence of events after (dis)continuing therapy, the uncertain risk trade-off between events with major consequences, the variety of indications for therapy, the variety of comorbidities and patient characteristics, and prognostic uncertainty. As a result, healthcare professionals act defensively when considering discontinuation, due to concerns about being held accountable for potential thrombotic events. Uncertainty in decision-making results in reactive decision-making in response to triggers such as active bleeding, low performance score, recognition of the dying phase, and patient\u2019s preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study highlighted the complexity of decision-making regarding anticoagulant therapy in the last phase of life. This results, in practice, in reactive instead of proactive decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02692163251394875","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:49:44Z","timestamp":1764154184000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Decision-making regarding anticoagulant therapy in the last phase of life: In-depth interview study with healthcare professionals (the OPTIMA trial)"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-1111","authenticated-orcid":false,"given":"Marte A. M.","family":"van Hylckama Vlieg","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn J. I.","family":"de Beukelaar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy H. L.","family":"Spreeuw","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H. A.","family":"Kruip","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"Department of Quality and Patient Care, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Hugo M. van der","family":"Kuy","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes van der","family":"Heide","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin C. D.","family":"van der Rijt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-2220","authenticated-orcid":false,"given":"Eric C. T.","family":"Geijteman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5223"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.220919"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2016.01.015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1330-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-021-00786-3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.02.028"},{"key":"e_1_3_3_8_2","article-title":"Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease","author":"Kempers EK","year":"2025","unstructured":"Kempers EK, Visser C, Geijteman ECT, et al Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease. Thromb Haemost 2025. DOI:10.1055\/a-2524-5334","journal-title":"Thromb Haemost"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2016.0487"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2021.0560"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0289"},{"key":"e_1_3_3_12_2","first-page":"600","article-title":"STOPPFrail (Screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation","volume":"46","author":"Lavan AH","year":"2017","unstructured":"Lavan AH, Gallagher P, Parsons C, et al STOPPFrail (Screening tool of older persons prescriptions in frail adults with limited life expectancy): consensus validation. Age Ageing 2017; 46: 600\u2013607.","journal-title":"Age Ageing"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2024.07.029"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1725115"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105143"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.12.028"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13606"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-001804"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2022.0069"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.09.023"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70032"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","DOI":"10.3390\/life12050613","article-title":"Deprescribing in Palliative Cancer Care","volume":"12","author":"Hedman C","year":"2022","unstructured":"Hedman C, Frisk G, Bj\u00f6rkhem-Bergman L. Deprescribing in Palliative Cancer Care. Life 2022; 12(5): 613.","journal-title":"Life"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076246"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-12-75"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6939-13-22"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.3384"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2019-001861"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909107310142"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-021-00809-z"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0907-4"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317887"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.1320"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309630"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.002696"},{"key":"e_1_3_3_39_2","first-page":"14363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan F","year":"2019","unstructured":"Khan F, Rahman A, Carrier M, et al Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019; 366: 14363.","journal-title":"BMJ"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.007"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1807262"},{"key":"e_1_3_3_42_2","first-page":"102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg MAM","year":"2023","unstructured":"van Hylckama Vlieg MAM, Nasserinejad K, Visser C, et al The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. med 2023; 64: 102194.","journal-title":"med"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02842-3"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416112"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S174896"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7498.1007"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076625"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.05.008"}],"container-title":["Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163251394875","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02692163251394875","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02692163251394875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:38:02Z","timestamp":1777660682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02692163251394875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/02692163251394875"],"URL":"https:\/\/doi.org\/10.1177\/02692163251394875","relation":{},"ISSN":["0269-2163","1477-030X"],"issn-type":[{"value":"0269-2163","type":"print"},{"value":"1477-030X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}